Unoprostone

Unoprostone (INN), classified as a prostaglandin analogue, has garnered attention in ophthalmic pharmacology. Its isopropyl ester derivative, unoprostone isopropyl, is marketed under the brand name "Rescula" in a 0.15% eye drop formulation. Its primary applications include the management and treatment of open-angle glaucoma and ocular hypertension.

Chemical Classification and Structure

Unoprostone is part of the prostaglandin family, which includes lipid compounds exhibiting a wide spectrum of physiological properties. These molecules, derived enzymatically from fatty acids, significantly impact several physiological and pathological processes.

Therapeutic Applications

Open-angle Glaucoma

Open-angle glaucoma, prevalent among glaucoma types, arises from the gradual blockage of the eye's drainage channels, leading to increased eye pressure. Unoprostone, by promoting the outflow of aqueous humor, assists in reducing this pressure, thus lowering the optic nerve damage risk.

Ocular Hypertension

In ocular hypertension, where there's increased intraocular pressure without evident optic nerve damage or vision loss, unoprostone offers therapeutic benefits by managing this elevated pressure.

Formulation and Administration

The commercialized derivative, unoprostone isopropyl, comes as "Rescula" eye drops with a 0.15% concentration. Typically, an ophthalmologist determines the administration frequency and dosage based on the disease's severity.

Side Effects and Precautions

Unoprostone, akin to its prostaglandin analogues, may trigger side effects. Common manifestations include ocular irritation, redness, and potential eyelash growth alterations. It remains crucial for patients to maintain regular consultations with their ophthalmologist throughout the treatment.

See Also

• Prostaglandins
• Glaucoma
• Ocular therapeutics

References

• FDA consumer information on Rescula